427 related articles for article (PubMed ID: 30452687)
1. Nivolumab and stereotactic radiation therapy for the treatment of patients with Stage IV non-small-cell lung cancer.
Miyamoto S; Nomura R; Sato K; Awano N; Kuse N; Inomata M; Izumo T; Terada Y; Furuhata Y; Bae Y; Kunitoh H
Jpn J Clin Oncol; 2019 Feb; 49(2):160-164. PubMed ID: 30452687
[TBL] [Abstract][Full Text] [Related]
2. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Hellmann MD; Rizvi NA; Goldman JW; Gettinger SN; Borghaei H; Brahmer JR; Ready NE; Gerber DE; Chow LQ; Juergens RA; Shepherd FA; Laurie SA; Geese WJ; Agrawal S; Young TC; Li X; Antonia SJ
Lancet Oncol; 2017 Jan; 18(1):31-41. PubMed ID: 27932067
[TBL] [Abstract][Full Text] [Related]
3. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
4. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial.
Peters S; Felip E; Dafni U; Belka C; Guckenberger M; Irigoyen A; Nadal E; Becker A; Vees H; Pless M; Martinez-Marti A; Tufman A; Lambrecht M; Andratschke N; Piguet AC; Kassapian M; Roschitzki-Voser H; Rabaglio-Poretti M; Stahel RA; Vansteenkiste J; De Ruysscher D
Lung Cancer; 2019 Jul; 133():83-87. PubMed ID: 31200833
[TBL] [Abstract][Full Text] [Related]
5. Accelerated-interrupted radiation therapy given concurrently with chemotherapy for locally advanced non-small cell lung cancer.
Ajlouni M; Chapman R; Kim JH
Cancer J Sci Am; 1996; 2(6):314-20. PubMed ID: 9166551
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab and ipilimumab with concurrent stereotactic radiosurgery for intracranial metastases from non-small cell lung cancer: analysis of the safety cohort for non-randomized, open-label, phase I/II trial.
Altan M; Wang Y; Song J; Welsh J; Tang C; Guha-Thakurta N; Blumenschein GR; Carter BW; Wefel JS; Ghia AJ; Yeboa DN; McAleer MF; Chung C; Woodhouse KD; McGovern SL; Wang C; Kim BYS; Weinberg JS; Briere TM; Elamin YY; Le X; Cascone T; Negrao MV; Skoulidis F; Ferrarotto R; Heymach JV; Li J
J Immunother Cancer; 2023 Jul; 11(7):. PubMed ID: 37402581
[TBL] [Abstract][Full Text] [Related]
7. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
Wrangle JM; Velcheti V; Patel MR; Garrett-Mayer E; Hill EG; Ravenel JG; Miller JS; Farhad M; Anderton K; Lindsey K; Taffaro-Neskey M; Sherman C; Suriano S; Swiderska-Syn M; Sion A; Harris J; Edwards AR; Rytlewski JA; Sanders CM; Yusko EC; Robinson MD; Krieg C; Redmond WL; Egan JO; Rhode PR; Jeng EK; Rock AD; Wong HC; Rubinstein MP
Lancet Oncol; 2018 May; 19(5):694-704. PubMed ID: 29628312
[TBL] [Abstract][Full Text] [Related]
8. A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study.
Bestvina CM; Pointer KB; Karrison T; Al-Hallaq H; Hoffman PC; Jelinek MJ; Juloori A; Melotek JM; Murgu S; Partouche J; Vokes EE; Weichselbaum RR; Pitroda SP; Patel JD; Chmura SJ
J Thorac Oncol; 2022 Jan; 17(1):130-140. PubMed ID: 34500113
[TBL] [Abstract][Full Text] [Related]
9. A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer.
Mattes MD; Eubank TD; Almubarak M; Wen S; Marano GD; Jacobson GM; Ma PC
Clin Lung Cancer; 2021 Jul; 22(4):268-273. PubMed ID: 33608212
[TBL] [Abstract][Full Text] [Related]
10. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
[TBL] [Abstract][Full Text] [Related]
11. Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases.
Ahmed KA; Kim S; Arrington J; Naghavi AO; Dilling TJ; Creelan BC; Antonia SJ; Caudell JJ; Harrison LB; Sahebjam S; Gray JE; Etame AB; Johnstone PA; Yu M; Perez BA
J Neurooncol; 2017 Jun; 133(2):331-338. PubMed ID: 28466250
[TBL] [Abstract][Full Text] [Related]
12. Outcome Study of Cobalt Based Stereotactic Body Radiation Therapy for Patients with Inoperable Stage III Non-small Cell Lung Cancer.
Wang Y; Lan F; Kang X; Shao Y; Li H; Li P; Wu W; Wang J; Chang D; Wang Y; Xia T
Technol Cancer Res Treat; 2015 Oct; 14(5):539-45. PubMed ID: 24750001
[TBL] [Abstract][Full Text] [Related]
13. [Stereotactic body radiaton therapy for 15 patients with small lung neoplasms].
Yu R; Li Y; Zhu G
Zhongguo Fei Ai Za Zhi; 2011 Mar; 14(3):266-70. PubMed ID: 21426671
[TBL] [Abstract][Full Text] [Related]
14. Radiotherapy is an independent prognostic marker of favorable prognosis in non-small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab.
Yamaguchi O; Kaira K; Hashimoto K; Mouri A; Miura Y; Shiono A; Nishihara F; Murayama Y; Noda SE; Kato S; Kobayashi K; Kagamu H
Thorac Cancer; 2019 Apr; 10(4):992-1000. PubMed ID: 30888716
[TBL] [Abstract][Full Text] [Related]
15. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG; Steuer CE; Owonikoko TK; Ramalingam SS; Bradley JD; Curran WJ
J Thorac Oncol; 2017 Nov; 12(11):1687-1695. PubMed ID: 28919394
[TBL] [Abstract][Full Text] [Related]
16. Radical stereotactic radiosurgery with real-time tumor motion tracking in the treatment of small peripheral lung tumors.
Collins BT; Erickson K; Reichner CA; Collins SP; Gagnon GJ; Dieterich S; McRae DA; Zhang Y; Yousefi S; Levy E; Chang T; Jamis-Dow C; Banovac F; Anderson ED
Radiat Oncol; 2007 Oct; 2():39. PubMed ID: 17953752
[TBL] [Abstract][Full Text] [Related]
17. Unusual skin toxicity associated with sustained disease response induced by nivolumab in a patient with non-small cell lung cancer.
Galli G; Proto C; Cossa M; Valeri B; Sdao S; Signorelli D; Imbimbo M; de Braud F; Garassino MC; Lo Russo G
Tumori; 2019 Dec; 105(6):NP57-NP62. PubMed ID: 31456503
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia: A multicenter, open-label single-arm phase II trial.
Fujimoto D; Yomota M; Sekine A; Morita M; Morimoto T; Hosomi Y; Ogura T; Tomioka H; Tomii K
Lung Cancer; 2019 Aug; 134():274-278. PubMed ID: 31182249
[TBL] [Abstract][Full Text] [Related]
19. Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: A multicentric retrospective study from the GFPC.
Lesueur P; Escande A; Thariat J; Vauléon E; Monnet I; Cortot A; Lerouge D; Danhier S; Dô P; Dubos-Arvis C; Chouaïd C; Gervais R
Cancer Med; 2018 Nov; 7(11):5505-5513. PubMed ID: 30311424
[TBL] [Abstract][Full Text] [Related]
20. Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
Horinouchi H; Nishio M; Hida T; Nakagawa K; Sakai H; Nogami N; Atagi S; Takahashi T; Saka H; Takenoyama M; Katakami N; Tanaka H; Takeda K; Satouchi M; Isobe H; Maemondo M; Goto K; Hirashima T; Minato K; Sumiyoshi N; Tamura T
Cancer Med; 2019 Sep; 8(11):5183-5193. PubMed ID: 31353840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
